What did Cramer say about Abbott Laboratories?

He said no one disputes the company's scientific and commercial smarts, calling it a legendary growth company in MedTech.

Is this a buy recommendation?

No, the statement is positive but not an official buy recommendation. Investors should conduct their own analysis.

Jim Cramer Praises Abbott Laboratories' Science and Commercial Smarts

Financial commentator Jim Cramer praised Abbott Laboratories (ABT) during a recent show, calling it a legendary growth company in MedTech and highlighting its undisputed scientific and commercial acumen.

June 4, 2026

2 min read

Source: Insider Monkey

In a recent episode of his show, Jim Cramer discussed Abbott Laboratories (NYSE:ABT) amid a broader conversation about the rally in AI-related stocks. Cramer described the company as one of the "legendary growth companies" in the medical technology (MedTech) sector, alongside Boston Scientific and others.

Details of the Statement

Cramer said: "Let's talk about some legendary growth companies and what's happened to their stocks. Consider three really high-quality MedTech companies: Abbott Labs, Boston Scientific, and..." He added: "No one disputes the science and commercial smarts of Abbott."

Context

Cramer's comments come amid intense competition in the MedTech space, where Abbott continues to innovate in areas like glucose monitoring and cardiac devices. The stock (ABT) is currently trading in a stable range, with investors focused on upcoming financial results.

What This Means for Investors

Cramer's endorsement reinforces confidence in the company's strong fundamentals, but it does not constitute a buy recommendation. Investors are encouraged to evaluate financial data and forward guidance before making any decisions.

Frequently Asked Questions

Jim Cramer is a financial commentator and host of CNBC's Mad Money, known for his investment analysis and recommendations.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.